Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2008-03-10 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: ORTHEZ (64300), Pyrenees-Atlantiques
PHARMACIE MONCADE : revenue, balance sheet and financial ratios
PHARMACIE MONCADE is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in ORTHEZ (64300),
this company of category PME
shows in 2024 a revenue of 3.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE MONCADE (SIREN 503133050)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
3 460 937 €
3 255 317 €
2 954 671 €
2 755 176 €
2 664 757 €
N/C
2 535 101 €
2 452 408 €
Net income
113 353 €
96 035 €
117 821 €
118 411 €
90 515 €
148 924 €
189 067 €
178 296 €
EBITDA
171 342 €
142 848 €
175 982 €
176 259 €
141 982 €
N/C
268 722 €
264 517 €
Net margin
3.3%
3.0%
4.0%
4.3%
3.4%
N/C
7.5%
7.3%
Revenue and income statement
In 2024, PHARMACIE MONCADE achieves revenue of 3.5 M€. Over the period 2017-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +5.0%. Vs 2023: +6%. After deducting consumption (2.6 M€), gross margin stands at 903 k€, i.e. a rate of 26%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 171 k€, representing 5.0% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 113 k€, i.e. 3.3% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2024)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
3 460 937 €
Gross margin (2024)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
903 193 €
EBITDA (2024)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
171 342 €
EBIT (2024)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
145 311 €
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
113 353 €
EBITDA margin (2024)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
5.0%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 17%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 62%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.4 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 3.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
16.594%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
62.365%
Cash flow / Revenue (2024)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
3.87%
Repayment capacity (2024)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
1.369
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
110.693
81.652
71.446
57.37
38.358
30.28
19.193
16.594
Financial autonomy
35.866
42.348
47.788
50.844
56.162
59.569
63.841
62.365
Repayment capacity
3.396
2.72
None
4.467
2.664
2.241
1.787
1.369
Cash flow / Revenue
7.185%
7.954%
None%
3.909%
4.658%
4.442%
3.397%
3.87%
Sector positioning
Debt ratio
16.592024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good
In 2024, the debt ratio of PHARMACIE MONCADE (16.59) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
62.37%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good
In 2024, the financial autonomy of PHARMACIE MONCADE (62.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
1.37 years2024
2022
2023
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Good
In 2024, the repayment capacity of PHARMACIE MONCADE (1.37) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 160.21. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 2.1x. Financial charges are adequately covered by operations.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
160.214
Interest coverage (2024)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
2.096
Liquidity indicators evolution PHARMACIE MONCADE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
135.319
160.226
211.668
195.753
177.904
188.619
179.118
160.214
Interest coverage
5.081
4.443
None
6.332
4.242
3.369
3.04
2.096
Sector positioning
Liquidity ratio
160.212024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average-5 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE MONCADE (160.21) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
2.1x2024
2022
2023
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Average-11 pts over 3 years
In 2024, the interest coverage of PHARMACIE MONCADE (2.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 3 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 48 days. Excellent situation: suppliers finance 45 days of the operating cycle (retail model). Inventory turnover is 22 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 22 days of revenue, i.e. 215 k€ to permanently finance. Over 2017-2024, WCR increased by +187%, requiring additional financing.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
215 097 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
3 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
48 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
22 j
WCR in days of revenue (2024)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
22 j
WCR and payment terms evolution PHARMACIE MONCADE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
75 019 €
143 690 €
0 €
178 379 €
118 307 €
109 943 €
145 513 €
215 097 €
Inventory turnover (days)
25
27
0
26
26
22
21
22
Customer payment term (days)
5
6
0
0
0
2
2
3
Supplier payment term (days)
41
46
0
42
40
42
41
48
Positioning of PHARMACIE MONCADE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE MONCADE is estimated at
1 771 795 €
(range 1 295 357€ - 2 540 421€).
With an EBITDA of 171 342€, the sector multiple of 9.2x is applied.
The price/revenue ratio is 0.64x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1295k€1771k€2540k€
1 771 795 €Range: 1 295 357€ - 2 540 421€
NAF 5 année 2024
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
171 342 €×9.2x
Estimation1 582 251 €
1 036 445€ - 2 460 075€
Revenue Multiple30%
3 460 937 €×0.64x
Estimation2 213 906 €
1 855 768€ - 2 789 613€
Net Income Multiple20%
113 353 €×14.0x
Estimation1 582 492 €
1 102 022€ - 2 367 498€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE MONCADE with other companies in the same sector:
Frequently asked questions about PHARMACIE MONCADE
What is the revenue of PHARMACIE MONCADE ?
The revenue of PHARMACIE MONCADE in 2024 is 3.5 M€.
Is PHARMACIE MONCADE profitable?
Yes, PHARMACIE MONCADE generated a net profit of 113 k€ in 2024.
Where is the headquarters of PHARMACIE MONCADE ?
The headquarters of PHARMACIE MONCADE is located in ORTHEZ (64300), in the department Pyrenees-Atlantiques.
Where to find the tax return of PHARMACIE MONCADE ?
The tax return of PHARMACIE MONCADE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE MONCADE operate?
PHARMACIE MONCADE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart